Publications by authors named "Daniel J George"

100Publications

The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.

Cancer J 2020 Sep/Oct;26(5):376-381

From the Duke Cancer Institute and the DCI Center for Prostate and Urologic Cancers, and Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000469DOI Listing
September 2020

Racial Disparity in Response to Prostate Cancer Systemic Therapies.

Curr Oncol Rep 2020 Jul 23;22(9):96. Epub 2020 Jul 23.

Duke Cancer Institute, Center for Prostate & Urologic Cancers, Duke University, Duke Box 103861, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-00966-zDOI Listing
July 2020

Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.

Clin Adv Hematol Oncol 2020 Apr;18(4):204-207

Duke Cancer Institute Center for Prostate and Urologic Cancers, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
April 2020

The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.

Cancer Treat Res Commun 2020 12;24:100183. Epub 2020 Jun 12.

City of Hope Comprehensive Cancer Center, Los Angeles, CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100183DOI Listing
June 2020

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Clin Genitourin Cancer 2020 Apr 10. Epub 2020 Apr 10.

Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.03.020DOI Listing
April 2020

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

N Engl J Med 2020 06 29;382(23):2187-2196. Epub 2020 May 29.

From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2004325DOI Listing
June 2020

Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.

Biosens Bioelectron 2020 Aug 1;162:112250. Epub 2020 May 1.

Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, Madison, WI, 53705, USA; Yonsei Frontier Lab and Department of Pharmacy, Yonsei University, Seoul, 03722, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bios.2020.112250DOI Listing
August 2020

Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.

Bioorg Med Chem Lett 2020 06 28;30(11):127148. Epub 2020 Mar 28.

Department of Chemistry, Duke University, Durham, NC 27708-0354 USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2020.127148DOI Listing
June 2020

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Eur Urol Oncol 2020 Feb 13. Epub 2020 Feb 13.

Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Pharmacology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Cancer Biology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2020.01.005DOI Listing
February 2020

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

Clin Genitourin Cancer 2020 08 7;18(4):284-294. Epub 2020 Jan 7.

Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.12.019DOI Listing
August 2020

Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.

Future Oncol 2020 Feb 10;16(4):39-47. Epub 2020 Jan 10.

Duke University Medical Center, Division of Oncology, 20 Duke Medicine Circle, Durham, NC 27710-4000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0369DOI Listing
February 2020

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

Urol Oncol 2020 03 12;38(3):79.e15-79.e22. Epub 2019 Sep 12.

Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Department of Medicine/Division of Medical Oncology, Duke University, Durham, NC; Department of Surgery/Division of Urology, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.08.015DOI Listing
March 2020

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

Prostate 2019 11 9;79(15):1752-1761. Epub 2019 Sep 9.

Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23899DOI Listing
November 2019

Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.

Authors:
Daniel J George

Clin Adv Hematol Oncol 2019 Jul;17(7):382-385

Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
July 2019

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Urol Oncol 2019 11 19;37(11):813.e1-813.e9. Epub 2019 Jul 19.

Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancer, Durham, NC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.06.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823135PMC
November 2019

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

J Clin Oncol 2019 08 2;37(24):2184-2186. Epub 2019 Jul 2.

Andrew J. Armstrong, MD, ScM and Susan Halabi, PhD, Duke University, Durham, NC; Jun Luo, PhD, Johns Hopkins University, Baltimore, MD; David M. Nanus, MD, Weill Cornell Medical College, New York, NY; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Emmanuel S. Antonarakis, MD, Johns Hopkins University, Baltimore, MD; and Daniel J. George, MD, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01230DOI Listing
August 2019

All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:302-308. Epub 2019 May 17.

6 University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/EDBK_238879
Publisher Site
http://dx.doi.org/10.1200/EDBK_238879DOI Listing
January 2019

Prostate Cancer National Summit's Call to Action.

Clin Genitourin Cancer 2019 06 16;17(3):161-168. Epub 2019 Apr 16.

Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.04.002DOI Listing
June 2019

Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.

Prostate 2019 07 2;79(10):1106-1116. Epub 2019 May 2.

Department of Medicine and Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23822DOI Listing
July 2019

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Prostate Cancer Prostatic Dis 2019 12 12;22(4):588-592. Epub 2019 Apr 12.

Division of Medical Oncology, Departments of Medicine, Duke Prostate and Urologic Cancer Center, Duke University and the Duke Cancer Institute, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0144-3
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0144-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853838PMC
December 2019

Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary.

Authors:
Daniel J George

Clin Adv Hematol Oncol 2019 Apr;17 Suppl 8(4):17-19

Divisions of Medical Oncology and Urology, Duke University School of Medicine, Durham, North Carolina.

View Article

Download full-text PDF

Source
April 2019

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 06 5;17(3):e513-e521. Epub 2019 Feb 5.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193004
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004481PMC
June 2019

The promise of immunotherapy in genitourinary malignancies.

Precis Clin Med 2018 Dec 19;1(3):97-101. Epub 2018 Dec 19.

Duke Cancer Institute, Duke University School of Medicine, Durham, NC.

View Article

Download full-text PDF

Source
https://academic.oup.com/pcm/article/1/3/97/5253459
Publisher Site
http://dx.doi.org/10.1093/pcmedi/pby018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333044PMC
December 2018

Precision Medicine Approaches When Prostate Cancer Akts Up.

Clin Cancer Res 2019 02 11;25(3):901-903. Epub 2018 Sep 11.

Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2491DOI Listing
February 2019

Information Transparency in the Drug Approval Process.

JAMA Oncol 2018 11;4(11):1621-1622

Duke Cancer Institute, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.4143DOI Listing
November 2018

Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.

Angew Chem Int Ed Engl 2018 09 29;57(39):12780-12784. Epub 2018 Aug 29.

Duke University, Department of Chemistry, POB 90346, Durham, 27708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201807582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372289PMC
September 2018

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Clin Genitourin Cancer 2018 10 25;16(5):341-348. Epub 2018 Apr 25.

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175670PMC
October 2018

How we treat brain metastases in metastatic renal cell carcinoma.

Clin Adv Hematol Oncol 2018 Feb;16(2):110-114

Duke Cancer Institute and Duke University School of Medicine, Durham, North Carolina.

View Article

Download full-text PDF

Source
February 2018

Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.

Clin Genitourin Cancer 2018 06 23;16(3):e509-e512. Epub 2018 Feb 23.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183010
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.02.017DOI Listing
June 2018

Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.

Target Oncol 2018 02;13(1):1-20

Division of Medical Oncology, Duke University School of Medicine, Duke Cancer Institute, Duke Box 3198, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11523-017-0549-7
Publisher Site
http://dx.doi.org/10.1007/s11523-017-0549-7DOI Listing
February 2018

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

J Immunother Cancer 2018 01 29;6(1). Epub 2018 Jan 29.

Department of Hematology & Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave, Desk CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0319-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789686PMC
January 2018

Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.

Authors:
Daniel J George

Clin Adv Hematol Oncol 2017 Sep;15(9):690-694

Divisions of Medical Oncology and Urology, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
September 2017

Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2017 12 14;15(6):e1137-e1141. Epub 2017 Jul 14.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.005DOI Listing
December 2017

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Cancer Chemother Pharmacol 2017 03 25;79(3):611-619. Epub 2017 Feb 25.

Duke Cancer Institute, Duke University Medical Center, Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3256-2DOI Listing
March 2017

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

J Clin Oncol 2017 02 14;35(6):591-597. Epub 2016 Nov 14.

Toni K. Choueiri and Meghara K. Walsh, Dana-Farber Cancer Institute; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben L. Sanford, Alliance Statistics and Data Center and Duke University; Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Olwen Hahn, Alliance Protocol Operations Office, Chicago, IL; Darren R. Feldman and Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University Medical Center, Columbus, OH; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Eric J. Small, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; and Shaker Dakhil, University of Kansas Wichita, Wichita, KS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455807PMC
February 2017

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.

Ther Adv Urol 2016 Aug 2;8(4):272-278. Epub 2016 May 2.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, DUMC 103861, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756287216645314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131740PMC
August 2016

Cabozantinib in genitourinary malignancies.

Future Oncol 2017 Apr 15;13(8):755-765. Epub 2016 Nov 15.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0358DOI Listing
April 2017

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Urol Oncol 2016 12 17;34(12):530.e15-530.e21. Epub 2016 Oct 17.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.07.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464417PMC
December 2016

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

N Engl J Med 2016 12 9;375(23):2246-2254. Epub 2016 Oct 9.

From the Department of Medical Oncology, Bordeaux University Hospital, Bordeaux (A.R.), Department of Medical Oncology, Institut Gustave Roussy, Villejuif (B.E.), Medical Oncology, Centre Eugene Marquis, Rennes (B.L.), and Department of Urology, Bicêtre Hospital, Paris-Saclay University, Le Kremlin Bicêtre (J.-J.P.) - all in France; Department of Medicine, Memorial Sloan Kettering Cancer Center (R.J.M.), and Pfizer (K.R.) - both in New York; Department of Clinical and Experimental Medicine, University of Surrey, Surrey, United Kingdom (H.S.P.); Division of Medical Oncology, Duke Cancer Institute, Durham, NC (D.J.G.); Department of Urology, Ronald Reagan UCLA Medical Center, Los Angeles (A.J.P.), and Pfizer, La Jolla (X.L., J.-F.M.) - both in California; Spire Roding Hospital, London (A.P.); Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Department of Oncology, Aarhus University Hospital, Aarhus, Denmark (F.D.); Department of Urology, Charité Universitätsmedizin Berlin, Berlin (A.M.), and Department of Urology, University Hospital of Munich, Munich (M.S.) - both in Germany; Divisions of Oncology and Urology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Naples, Italy (G.C.); Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland (P.T.); Department of Urology, Slovak Medical University, Bratislava, Slovakia (J.B.); and Pfizer, Milan (P.G., M.L.), and Collegeville, PA (M.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611406DOI Listing
December 2016

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.

Asian J Urol 2016 Oct 6;3(4):268-277. Epub 2016 Sep 6.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajur.2016.08.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730869PMC
October 2016

Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.

Urol Oncol 2016 11 4;34(11):510-518. Epub 2016 Aug 4.

Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.06.020DOI Listing
November 2016

Development of a Novel c-MET-Based CTC Detection Platform.

Mol Cancer Res 2016 06 7;14(6):539-47. Epub 2016 Mar 7.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina. Department of Pharmacology and Cancer Biology, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-16-0011DOI Listing
June 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Clin Genitourin Cancer 2016 Feb 6;14(1):28-37.e2. Epub 2015 Aug 6.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Duke Cancer Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698191PMC
February 2016

The future of kidney cancer treatment.

Authors:
Daniel J George

Clin Adv Hematol Oncol 2015 Jun;13(6):368-71

Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
June 2015

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

J Oncol Pract 2015 Nov 1;11(6):491-7. Epub 2015 Sep 1.

Duke University Medical Center; Duke Clinical Research Institute, Durham, NC; and ACORN Research, Memphis, TN

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.004929DOI Listing
November 2015

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

J Clin Oncol 2015 Jul 15;33(21):2384-91. Epub 2015 Jun 15.

Keith T. Flaherty, University of Pennsylvania, Philadelphia, PA; Judith B. Manola, Dana-Farber Cancer Institute; David F. McDermott and Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA; Michael Pins, Advocate Lutheran General Hospital, Park Ridge, IL; Janice J. Dutcher, Montefiore Medical Center, Bronx, NY; Daniel J. George, Duke University Medical Center, Durham, NC; Kim A. Margolin, Seattle Cancer Care Alliance, University of Washington, Seattle, WA; and Robert S. DiPaola, Cancer Institute of New Jersey at Hamilton, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.9727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500832PMC
July 2015

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.

BMC Cancer 2015 May 7;15:371. Epub 2015 May 7.

Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1390-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426169PMC
May 2015

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.

Cancer Immunol Res 2015 Sep 5;3(9):1063-9. Epub 2015 May 5.

Department of Urology, Jefferson Kimmel Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0006DOI Listing
September 2015

Deferred systemic therapy in patients with metastatic renal cell carcinoma.

Clin Genitourin Cancer 2015 Jun 31;13(3):e159-66. Epub 2014 Dec 31.

Division of Medical Oncology, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.12.017DOI Listing
June 2015

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2015 Aug 24;13(4):392-399. Epub 2015 Jan 24.

Duke Cancer Institute, Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.01.004DOI Listing
August 2015

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Urol Oncol 2015 Mar 13;33(3):110.e1-9. Epub 2015 Jan 13.

Department of Medicine, Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439140031
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2014.09.002DOI Listing
March 2015

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Expert Opin Pharmacother 2015 Mar 23;16(4):473-85. Epub 2014 Dec 23.

Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Medicine , DUMC 3841, Durham, NC 27710 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2015.995090DOI Listing
March 2015

Copper signaling axis as a target for prostate cancer therapeutics.

Cancer Res 2014 Oct;74(20):5819-31

Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203427PMC
October 2014

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

J Clin Oncol 2014 Oct 15;32(30):3391-9. Epub 2014 Sep 15.

Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/09/15/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.5954
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.5954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383838PMC
October 2014

Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.

Med Oncol 2014 Sep 14;31(9):156. Epub 2014 Aug 14.

Division of Medical Oncology, Duke University Medical Center, DUMC Box 17969, Durham, NC, 27715, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-014-0156-8DOI Listing
September 2014